Business news: College Goal Sunday and Strollin' Through The Colon
Inflatable colon to pop up at Franciscan Munster
A 12-foot, walk-through inflatable colon is scheduled to be on display at Franciscan Health Munster later this month in an effort to help increase colon cancer awareness and highlight the benefits of colonoscopies, according to a release.
The free Strollin' Through the Colon will be on display from 9 a.m. to 3 p.m. Feb. 24-26 inside the main entrance at Franciscan Health Munster, 701 Superior Ave. Franciscan Health staff will be on hand with educational materials and giveaways, the release said.
The giant inflatable colon helps illustrate health issues that can impact the critical organ, including colon cancer, Crohn's disease, diverticulitis, colitis, internal hemorrhoids and polyps and how colonoscopy screenings can help detect them. For information, visit Franciscan Alliance website.
Conference seeks speaker nominations
Organizers of the 2025 Professional Women's Conference are currently offering opportunities for speakers for the next conference scheduled for Nov. 12, according to a release.
The event, which is presented by the Northwest Indiana Influential Women Association (NWIIWA), is seeking speakers to deliver insights about career development, workforce, professional empowerment topics, and more.
Prospective speakers can submit a nomination form to be considered to deliver one of several keynote addresses or lead an informative breakout session during the event. Submissions will be reviewed and considered for topics that align with the objectives of the conference, the release said
Nomination forms and more information about requirements for presenters are available at www.professionalwomensconference.com under the 'Get Involved' tab. Deadline to submit a nomination form is April 15.
Casino donates $25K to foundation
In honor of National Human Trafficking Awareness Month, Hard Rock Casino Northern Indiana's President and CEO Matt Schuffert recently presented a check for $25,000 to Jess Kern, Founder and President of the Raindrops Rising Foundation, a release said.
The mission of the Raindrops Rising Foundation is to inspire and reinforce a message of hope, advocating and raising awareness for sexual assault and human trafficking survivors every step of their journey, the release said.
Raindrops Rising Foundation is a nationwide non-profit organization based in Valparaiso. For more information, visit https://www.raindropsrisingfoundation.com/ .
Lake County Forever reports growth
Legacy Foundation officials Monday announced the Lake County Forever campaign has moved beyond the 82% point of its $1.9 million goal, according to a release.
The campaign is driven by a promise from the Lilly Endowment Inc., which will donate $2 for every $1 raised by Lake County Forever, the release said.
By the end of June, the campaign, with the 2-to-1 match, expects to raise nearly $6 million for Region nonprofits, the release said. The funds will go towards unrestricted funds, which go directly to nonprofits that address community needs throughout Lake County, the release said.
For more information on the Lake County Forever campaign, go to legacyfdn.org.
PNW to host College Goal Sunday event
Financial aid professionals will be on site at Purdue University Northwest's (PNW) Hammond and Westville campuses from 2-4 p.m. Feb. 23 during the statewide College Goal Sunday programs, according to a release.
College Goal Sunday programs provide assistance to students in filing the Free Application for Federal Student Aid (FAFSA). The FAFSA form is required for students to be considered for federal and state grants, scholarships and federal loans at most colleges, universities and vocational/technical schools nationwide.
The FAFSA form must be completed, filed and received by the federal processor on or before April 15, the release said.
For more information on College Goal Sunday, visit the College Goal Sunday website
Officer earns Dist. 10 honor
Indiana Conservation Officer Bryce Klimek, who serves Pulaski County, has been selected as 2024 District 10 Officer of the Year, according to a release.
Klimek has served as a conservation officer for 22 years. He served in Porter County before transferring to Pulaski County, the release said. In addition to his normal duties, Klimek serves as a field training officer, sonar operator, background investigator, and passenger for hire inspector, all for the Department of Natural Resources Division of Law Enforcement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Health New England to replace Humira coverage with lower-cost biosimilars
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health plans. Markey playing defense against GOP clean energy plans Effective July 1, the not-for-profit health insurer will cover Amjevita by Nuvaila and Hadlima instead of Humira, as part of a broader effort to manage rising health care costs while maintaining access to effective treatments. Humira is used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. 'Biologic medications like Humira are complex treatments that carry significant cost. Its biosimilars provide a meaningful opportunity to enhance affordability for the health care ecosystem while members continue to get the full benefits of the medication,' said Gary Tereso, PharmD, Director of Pharmacy Services at Health New England. Biologic drugs are made from living organisms and are typically more expensive than other medications. Biosimilars are developed to be nearly identical in safety, potency, and efficacy to the original biologic, but at a significantly lower cost. The shift in coverage is intended to make treatment more accessible and financially sustainable for members and employer groups alike. Health New England is directly reaching out to members who are currently prescribed Humira, along with their health care providers and pharmacies, to assist with the transition. The company said it will continue monitoring the biosimilar marketplace to ensure members receive both high-quality care and cost-effective treatment options. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
New York Post
05-06-2025
- New York Post
Joe Rogan among the fans of revolutionary anti-aging peptide
Highway to heal? An experimental peptide is in the spotlight for its potential to promote tissue repair, reduce inflammation and protect gut health. Count podcast host Joe Rogan, 57, among the fans of BPC-157 — he reported that it cleared up his elbow tendonitis in just two weeks. Biohackers hope its regenerative and anti-inflammatory powers lead to longer, healthier lives. 5 Podcast host Joe Rogan said BPC-157 cleared up his elbow tendonitis in just two weeks. Youtube / The Joe Rogan Experience 'The people who have tried it say it is life-changing,' Dr. Michael Aziz, an internist in New York and author of 'The Ageless Revolution,' told The Post. 'So is BPC-157 going to revolutionize physical therapy?' he mused. 'We hope the research comes soon.' Here's a look at the science behind the emerging therapy. What is BPC-157? BPC-157 is the short name for Body Protection Compound 157. It's comprised of 15 amino acids and derived from a naturally occurring protein in human stomach juice. Dr. Christian Muller, a sports medicine physician with Northwell Health Orthopedics in Westchester, said BPC-157 was discovered in the early '90s during research into substances that could protect the body from harm. 5 BPC-157 is in the spotlight for its potential to promote tissue repair, reduce inflammation and protect gut health. Amazon How it exactly works in the body is not fully understood. 'Research suggests BPC-157 may work by enhancing the formation of new blood vessels, which improves blood flow and nutrient delivery to injured tissues, accelerating healing,' Aziz said. 'It also influences the expression of various growth factors, such as growth hormone receptors, which are crucial for tissue repair and regeneration,' he added. Inside the potential benefits The Food and Drug Administration has not approved BPC-157, as much of the research has been conducted in animals. 'There are few, extremely limited studies on humans,' Muller told The Post. 'One study showed that knee injections with BPC-157 helped with arthritis pain in 11 out of 12 subjects, but the study did not use verified survey tools to obtain reliable answers regarding efficacy.' 5 BPC-157 may be able to help with recovery after a knee injury. Dragana Gordic – BPC-157 is being explored for: Tissue repair Healing of muscle, tendon, ligament and skin wounds Collagen production Neuroinflammation Nerve regeneration Arthritis Gastric ulcers Inflammatory bowel disease (Crohn's disease, ulcerative colitis) Leaky gut syndrome Irritable bowel syndrome 'Had a recent knee surgery? Had an injury at the gym and your doctor suggested physical therapy for six months? Not so fast. BPC-157 can help,' Aziz said. How much should you take? Dr. Pooja Gidwani, a double board-certified internal and obesity medicine physician based in L.A., noted that there are no standard doses because human data is limited. She suggested that oral forms of BPC-157 may be helpful for gut issues, while injections are typically preferred for systemic healing, such as joint or tendon recovery. She has 'nuanced conversations' with patients eager to try it. 5 How BPC-157 exactly works in the body is not fully understood. Research suggests that it may accelerate healing by enhancing the formation of new blood vessels. Sanhanat – 'We begin with an open, informed discussion about the current evidence — what's promising and what's unknown,' Gidwani told The Post. 'For some patients dealing with chronic gut issues, tendon injuries or post-operative healing challenges,' she continued, 'we discuss where the science currently stands and make a collaborative decision based on goals, risk tolerance and alternatives.' Some researchers recommend cycling it to prevent side effects. Andrew Huberman, a neuroscientist and professor of neurobiology and ophthalmology, suggests limiting BPC-157 usage to eight weeks and taking an eight-week break — or more. 'My concern about taking BPC157 continuously: it promotes vascular growth, and if you have a small tumor, it will vascularize that tumor as well. Not good,' Huberman tweeted in April. And beware if you purchase capsules online. 'Many times it is fake or not safe,' Aziz advised. Behind the possible downsides 'There are potential safety concerns, but given the lack of human data, they are not truly known,' Muller said. 'Since BPC-157 has been shown to be biologically active in several complex body processes,' he added, 'there can be a multitude of unknown potential dangers across several organ systems.' 5 New blood vessel growth may help promote healing, but it could also fuel tumors. phonlamaiphoto – Since it can cause uncontrolled growth of new blood vessels, people with a history of cancer or concerns about tumors should approach BPC-157 with caution. Because it has been shown to interact with growth hormone pathways, Aziz warned of potential hormonal disruption with extended use. It's also on the World Anti-Doping Agency's prohibited list for professional athletes because of its unproven claims and possible health risks. Scientists hope to learn more about it soon. 'Peptides like BPC-157 are part of an exciting frontier in longevity and regenerative medicine — but they're still evolving,' Gidwani said. 'It's not about hype — it's about understanding the potential while also respecting the limitations of what we know.'
Medscape
04-06-2025
- Medscape
Intestinal Ultrasound Wins in Early Crohn's Prognosis
Findings on intestinal ultrasound (IUS) are useful for predicting remission in recent-onset Crohn's disease (CD), a prospective, population-based cohort of newly diagnosed patients in Denmark reported. Adding to the growing body of evidence on the utility of this noninvasive imaging tool in monitoring disease activity in the newly diagnosed, the multicenter study published in Clinical Gastroenterology and Hepatology characterized ultrasonographic features at diagnosis and evaluated IUS's prognostic value. Existing literature has focused on patients with long-standing disease. Investigators led by first author Gorm R. Madsen, MD, PhD, of the Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults at Copenhagen University Hospital, observed continued improvement in most IUS parameters throughout the first year. 'Our findings thereby emphasize the role of IUS in improving patient management, and its use in patient risk stratification already at diagnosis,' the investigators wrote. Some 38% of patients reached ultrasonic transmural remission within 3 months of diagnosis, an achievement associated with higher rates of sustained steroid-free clinical remission and reduced need for treatment escalation. 'Ultrasonic transmural remission is achievable early in Crohn's disease and is associated with favorable outcomes, underscoring the value of intestinal ultrasound in early disease management,' the researchers wrote. Study Details While IUS is increasingly recognized for monitoring CD, little was known about its prognostic value early in the disease course. 'We aimed to determine whether sonographic inflammation at diagnosis — and particularly the achievement pftransmural remission after 3 months — could predict future outcomes,' Madsen told Medscape Medical News . 'This is important, as early identification of patients at risk of surgery or treatment escalation may help guide therapy decisions more effectively.' From May 2021 to April 2023, 201 patients (mean age, 35 years; 54.2% men) with new adult-onset CD were followed by IUS and monitored with symptomatic, biochemical, and endoscopic evaluations. After 3 months, transmural remission was achieved more often by patients with colonic disease, and no associations were found between sonographic inflammation at diagnosis and diagnostic delay. 'We were positively surprised. Nearly 40% of newly diagnosed Crohn's patients achieved transmural remission within 3 months — a higher proportion than seen in earlier studies, which mostly focused on long-standing or trial-selected populations,' Madsen said. 'It was also striking how strongly early IUS findings predicted the need for surgery, outperforming endoscopy and biomarkers.' In other findings, transmural remission at 3 months was significantly associated with steroid-free clinical remission at both 3 months and all subsequent follow-ups within the first year. It was also linked to a lower risk for treatment escalation during the follow-up through to 12 months: 26% vs 53% ( P =.003). At 12 months, 41% had achieved transmural remission. Higher baseline body mass index significantly reduced the likelihood of 12-month transmural remission. For overweight, the odds ratio (OR) was 0.34 (95% CI, 0.12-0.94), while for obesity, the OR was 0.16 (95% CI, 0.04-0.73). The International Bowel Ultrasound Segmental Activity Score in the terminal ileum at diagnosis emerged as the best predictor of ileocecal resection during the first year, with an optimal threshold of 63 (area under the curve, 0.92; sensitivity, 100%; specificity, 73%). The use of IUS has expanded considerably in the past 3 years, and in 2024, the American Gastroenterological Association updated its clinical practice guidance on the role of this modality in inflammatory bowel disease. IUS is noninvasive, radiation-free, inexpensive, and doable at the bedside with immediate results, Madsen said. 'For patients, this means less anxiety and discomfort. For healthcare systems, it enables faster clinical decisions, reduced need for endoscopy or MRI, and closer disease monitoring, particularly valuable in treat-to-target strategies.' In terms of limitations, however, IUS is operator-dependent and consistent training is crucial, he added. 'Certain anatomical regions, particularly the proximal small bowel, can be more challenging to evaluate. Additionally, while IUS is highly effective for assessing inflammatory activity, it becomes more difficult to accurately assess disease involvement when inflammation extends beyond approximately 20 cm of the small bowel.' Key Insights Commenting on the Danish study from a US perspective, Anna L. Silverman, MD, a gastroenterology fellow at Icahn School of Medicine at Mount Sinai in New York City, agreed the findings in adult patients with newly diagnosed, rather than long-standing, CD contribute to the growing body of evidence supporting IUS's applicability for both treatment monitoring and prognosis. 'By focusing on early-stage CD, the study provides clearer insights into initial disease activity and response to therapy, reinforcing the value of this noninvasive, point-of-care modality,' she told Medscape Medical News . 'These findings enhance our understanding of IUS as a tool to help guide early management decisions in CD.' Ashwin Ananthakrishnan, MBBS, MPH, director of the Crohn's and Colitis Center at Massachusetts General Hospital and an associate professor at Harvard Medical School, both in Boston, concurred that this is an important study. 'It includes newly diagnosed patients — so a very 'clean' cohort in terms of not being influenced by confounders,' he told Medscape Medical News . 'We don't fully know yet the best treatment target in CD, and this study highlights the importance of early transmural healing in determining outcomes at 1 year,' he noted. In addition, the study highlighted a convenient tool that can increasingly be applied at point of care in the United States. 'Colonoscopy at 3 months is not practical and has low patient acceptability, so using IUS in this circumstance would have value and impact.' Ananthakrishnan pointed to several unanswered questions, however. 'Are there patients who may not have healing early but may take some extra time to achieve transmural remission, and if so, what are their outcomes? What is the best timepoint for transmural healing assessment? What is the incremental value of measuring it at 3 vs 6 months?' In addition, he wondered, how much is the added value of IUS over clinical symptoms and/or markers such as calprotectin and C-reactive protein? 'In the subset of patients with clinical and transmural remission, there was no difference in endoscopic outcomes at 1 year, so this is an unanswered question,' Ananthakrishnan said. This study was funded by an unrestricted grant from the Novo Nordisk Foundation.
